Stephen Carey Sells 2,850 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen Carey sold 2,850 shares of ANI Pharmaceuticals stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $81.36, for a total value of $231,876.00. Following the transaction, the chief financial officer owned 174,693 shares of the company’s stock, valued at $14,213,022.48. The trade was a 1.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Down 1.5%

Shares of ANIP opened at $79.24 on Friday. ANI Pharmaceuticals, Inc. has a 52 week low of $62.60 and a 52 week high of $99.50. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06. The company has a market capitalization of $1.80 billion, a price-to-earnings ratio of 20.06 and a beta of 0.43. The stock’s 50-day moving average price is $81.13 and its 200-day moving average price is $79.52.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The firm had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. During the same period last year, the company earned $1.70 earnings per share. ANI Pharmaceuticals’s revenue for the quarter was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on ANIP shares. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Canaccord Genuity Group began coverage on shares of ANI Pharmaceuticals in a research note on Thursday, July 16th. They set a “hold” rating and a $91.00 target price on the stock. Guggenheim restated a “buy” rating and issued a $124.00 price target on shares of ANI Pharmaceuticals in a research note on Friday, July 10th. Finally, Weiss Ratings raised ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, June 23rd. Six research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $105.00.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the stock. Advisors Asset Management Inc. acquired a new stake in shares of ANI Pharmaceuticals in the first quarter valued at about $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of ANI Pharmaceuticals by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock worth $736,000 after purchasing an additional 470 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of ANI Pharmaceuticals by 0.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock worth $3,235,000 after purchasing an additional 423 shares during the last quarter. Jane Street Group LLC purchased a new position in ANI Pharmaceuticals in the 1st quarter valued at about $2,706,000. Finally, Norges Bank purchased a new position in ANI Pharmaceuticals in the 2nd quarter valued at about $625,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.